Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other Accumulated Expenses (2022 - 2023)

Historic Other Accumulated Expenses for InMed Pharmaceuticals (INM) over the last 2 years, with Q1 2023 value amounting to $2.3 million.

  • InMed Pharmaceuticals' Other Accumulated Expenses changed N/A to $2.3 million in Q1 2023 from the same period last year, while for Mar 2023 it was $2.3 million, marking a year-over-year change of. This contributed to the annual value of $3.2 million for FY2022, which is N/A changed from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Other Accumulated Expenses of $2.3 million as of Q1 2023.
  • In the past 5 years, InMed Pharmaceuticals' Other Accumulated Expenses ranged from a high of $3.3 million in Q3 2022 and a low of $2.3 million during Q1 2023